Novo Nordisk takes its first step into RNA with a broad cardio-metabolic deal with Dicerna, the biggest sealed by the US biotech to date.
Novo Nordisk took an early step towards genome editing with yesterday’s Bluebird tie-up, and isn’t ruling out a move into conventional gene therapies.
The Danish company’s latest deal covers glucose-sensitive insulin, which could avoid hypoglycaemia in type 2 diabetes patients.
Drug discovery is getting harder, and some companies are turning to machine learning to look for new targets.
Epigenetics has so far failed to live up to the hype. But one UK player, Storm Therapeutics, still hopes to make a mark in a new field, RNA therapeutics.
Immunocore and Adaptimmune could shortly have a publicly listed rival.